Atea Pharmaceuticals Inc (NAS:AVIR)
$ 3.71 -0.25 (-6.31%) Market Cap: 312.47 Mil Enterprise Value: -242.18 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 43/100

Atea Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 14, 2021 / 06:00PM GMT
Release Date Price: $27.72 (-0.57%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Good afternoon, everybody. Thanks for joining us for our next session. I'm Matthew Harrison, one of the Biotech Analysts here at Morgan Stanley. Very pleased to have Atea with us.

Before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures here on the Morgan Stanley public website at morganstanley.com/researchdisclosures. So thanks, everybody from Atea for being here.

I'm going to turn it over to JP to make some opening comments, and then we can jump right into the Q&A.

Jean;Pierre Sommadossi
Atea Pharmaceuticals, Inc. - Founder, Chairman, CEO & President

Thank you, Matthew, for this opportunity. And before we go into Q&A, I would like to just take a step back and provide some background about Atea. Since the founding of the Company, our vision has remained the same with the discovery and development of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot